FIRST LINE EUCOM - Outside UK/Scandinavia: VIPERFAV
SECOND LINE EUCOM - Inside UK/Scandinavia: VIPERFAV
Sanofi-Pasteur, France - Viperfav (VIPERFAV) (Freeze dried/Refrigerated) 206-212:
Feasibility of use in austere environments: Not recommended for operational settings. Requires cold chain refrigeration between 2 - 8 ºC (35.6 - 46.4 ºF). Recommend storing several vials at a small number of strategically located Role 2 & 3 facilities. Likely to retain efficacy for several weeks in the field but should be disposed of after that duration of time outside refrigeration.
Adverse reactions: High efficacy against all major syndromes and low incidence of serious adverse reactions based on current publications.
Indications: Polyvalent antivenom directly indicated for the treatment of neurotoxic, hemotoxic, and cytotoxic envenomation syndromes caused by Vipera berus, V. aspis, V. ammodytes but has demonstrated efficacy against other species of European vipers (genus Vipera) as well.
Pretreatment: Not routinely indicated unless patient is unstable, asthmatic/atopic, known hypersensitivity or other pretreatment criteria met. Low risk of severe allergic reactions and other EARs.
Initial dosing by syndrome:
Additional dosing: Additional doses of 1 vial VIPERFAV may be given at hours 2, 4, 6, 12, and 24 if needed.
Preparation and administration: Dilute the entire dose of antivenom in a single 250 - 500 mL bag of isotonic solution and administer by intravenous infusion over 10 - 30 minutes.
FIRST LINE EUCOM – Inside UK/Scandinavia: VIPERATAB
SECOND LINE EUCOM – Outside UK/Scandinavia: VIPERATAB
Micropharm, UK - ViperaTAb (VIPERATAB) (Freeze dried/Refrigerated) 206,210,213–215:
Feasibility of use in austere environments: Not recommended for operational settings. Requires cold chain refrigeration between 2 - 8 ºC (35.6 - 46.4 ºF). Recommend storing several vials at a small number of strategically located Role 2 & 3 facilities. Likely to retain efficacy for several weeks in the field but should be disposed of after that duration of time outside refrigeration.
Adverse reactions: High efficacy against UK / Scandinavian European viper (Vipera berus) envenomations and low incidence of serious adverse reactions based on current publications.
Indications: Polyvalent antivenom directly indicated for the treatment of neurotoxic, hemotoxic, and cytotoxic envenomation syndromes caused by Vipera berus. Has demonstrated efficacy against other species of European vipers (V. aspis, V. ammodytes) as well but is not directly indicated for these species.
Pretreatment: Not routinely indicated unless patient is unstable, asthmatic/atopic, known hypersensitivity or other pretreatment criteria met. Low risk of severe allergic reactions and other EARs.
Initial dosing by syndrome:
Additional dosing: Additional 2 vials VIPERATAB may be given at hours 2, 4, 6, 12, and 24 if needed.
Preparation and administration: Each box of VIPERATAB comes with two 4 mL vials of antivenom (one box = one dose). Dilute the entire dose of antivenom in a single 100 - 500 mL bag of isotonic solution and administer by intravenous infusion over 10 - 30 minutes.